Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Radar™  A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata Notes Completion of Acquisition by NeoGenomics

Research Triangle Park, NC, USA and Cambridge, UK, 18 June 2021 -- Inivata, a leader in liquid biopsy, today announces that ... Read More

Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach

Rosalind Cutts, Maria Coakley, Isaac Garcia-Murillas, Lara Ulrich, Karen Howarth, Warren Emmett, Malcolm Perry, Pete Ellis, Charlene ... Read More

2021 CB & CDx Digital Event

2021 CB & CDx Digital Event

Event expiration date display - 29 - 30 SEPT 2021

Location: Online Event Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

We’re delighted to join the @NeoGenomics family. Leveraging our combined resources will enable us to accelerate the development of our leading #liquidbiopsy tests including #RaDaR, the highly sensitive personalized assay for the detection of residual disease and recurrence.

We’re always looking for talented and ambitious individuals to join #TeamInivata. We have a variety of different positions available from research-based roles to marketing!

If you’re interested in joining the #liquidbiopsy revolution, get in touch: https://bit.ly/3u97jay

Last week the 2021 @EACRnews Virtual #Congress provided fascinating insights into a wide breadth of topics – including the potential of #cancer #diagnostics to revolutionize treatment. Get in touch to hear more about our #liquidbiopsy solution.